Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritobegron in Patients With Overactive Bladder
NCT00742833Phase 2
Key facts
- Status
- Completed
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- ritobegron
- Conditions
- overactive bladder (OAB)
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) comparing KUC-7483 with Placebo (2 arms). Primary endpoint: Change from baseline in mean number of micturitions per 24 hours at 12 weeks. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
KUC-7483
Experimental arm receiving KUC-7483
Placebo
Comparator arm receiving Placebo
03
Who it enrols
Patients with overactive bladder symptoms for >6 months, with >=8 micturitions/24h and >=1 urgency episode/24h.
04
Endpoints
Primary
Change from baseline in mean number of micturitions per 24 hours
Secondary
Change from baseline in mean number of urgency episodes per 24 hours
Change from baseline in mean number of incontinence episodes per 24 hours
Beyond the preview
Go deeper on NCT00742833.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742833.